{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"106.0","upperLimit":"106.0","value":"106.0"},{"groupId":"OG001","lowerLimit":"22","upperLimit":"85","value":"53.5"},{"groupId":"OG002","lowerLimit":"57","upperLimit":"106","value":"64.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Time to response per investigator assessment was defined as the time from date of first dose to the date of the first documented CR or PR. The tumor assessment was based on GRS Olsen 2011 criteria. CR was defined as disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites.","dispersionType":"Full Range","groups":[{"description":"Participants were treated with E7777 6 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG000","title":"Lead-In Part: E7777 6 mcg/kg"},{"description":"Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minute on 5 consecutive days during every 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-In Part.","id":"OG001","title":"Lead-In Part: E7777 9 mcg/kg"},{"description":"Participants were treated with E7777 12 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG002","title":"Lead-In Part: E7777 12 mcg/kg"},{"description":"Participants were treated with E7777 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG003","title":"Lead-In Part: E7777 15 mcg/kg"}],"paramType":"MEDIAN","populationDescription":"Lead-in analysis set included all participants enrolled in the Lead-in part. Here, 'overall number of participants analyzed' were those who had CR or PR in lead-in part of the study.","reportingStatus":"POSTED","timeFrame":"From the date of administration of the first dose of the study drug until date of the first documentation of PR or CR (Up to 1 year 2 months)","title":"Lead-In Part: Time to Response (TTR) Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"days"}